Should I Buy IMA? IMA 2026 Analysis

Should You Buy ImageneBio Inc (IMA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

7.390

1 Day change

52 Week Range

18.000

Analysis Updated At

2026/01/29

IMA is not a good buy right now for a beginner, long-term investor with $50k–$100k. The stock has short-term momentum, but the fundamental setup (no revenue, ongoing large losses, single-asset dependence) plus a very bearish recent analyst downgrade with a $2 target makes the risk/reward unattractive at today’s ~$7.35. If you want a long-term position, this is an avoid/exit rather than an add-now.

Technical Analysis

Trend/price action: Momentum is positive (MACD histogram +0.09 and expanding), but price is pressing into resistance and looks short-term stretched. RSI(6) is ~70.8, which is near overbought and often signals limited immediate upside. Key levels: Pivot 6.786. Support S1 6.255 (then S2 5.927). Resistance R1 7.317 (already slightly exceeded), next R2 7.645. Interpretation: With RSI elevated and price near/through R1, upside may be capped near ~7.65 unless a catalyst appears; downside risk back toward ~6.80–6.25 is meaningful. Intellectia Proprietary Trading Signals **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Positive Catalysts

Technical momentum is currently positive (MACD expanding) which can support short-term continuation.
A potential development partner or a shift to a new indication (explicitly cited as needed by the covering analyst) would be a meaningful upside catalyst.
Any unexpected clinical/regulatory update could re-rate the stock given the single-asset focus.

Neutral/Negative Catalysts

Analyst action is strongly negative: Wedbush downgraded to Underperform and slashed the price target to $2 from $23 (coverage initiation), citing high development costs, reliance on a single asset/indication, limited catalysts, and competitive products that may be as good or better.
Fundamentals show no revenue and continued heavy losses, implying ongoing funding/cash-burn risk.
No news in the last week and a limited catalyst calendar reduces the probability of near-term upside follow-through.

Financial Performance

Latest reported quarter: 2025/Q3. Revenue: 0 (no YoY growth). Net income: -$25.625M (improved YoY, but still a large loss). EPS: -3.01 (improved YoY, still deeply negative). Overall: financials reflect a pre-revenue biotech profile with continued losses; the improvement is not yet a durable growth trend because revenue remains zero.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Sharply deteriorating. On 2025-11-25, Wedbush (Martin Fan) downgraded IMA to Underperform from Neutral and cut the price target to $2 from $23. Wall Street pro view (pros/cons): Pros: If the company lands a development partner or pivots to a stronger indication, sentiment could improve quickly. Cons (dominant): High development costs, single-asset/indication concentration risk, limited upcoming catalysts, and competitive landscape concerns. Net takeaway: the lone, most recent professional view is decisively bearish and not aligned with a beginner long-term buy-now approach.

3 Analyst Rating

Wall Street analysts forecast IMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMA is 16 USD with a low forecast of 2 USD and a high forecast of 30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

1 Sell

Moderate Buy

Current: 7.390

Low

Averages

High

Current: 7.390

Low

Averages

High

Wedbush

Martin Fan

Neutral -> Underperform

downgrade

$23 -> $2

AI Analysis

2025-11-25

Reason

Wedbush

Martin Fan

Price Target

$23 -> $2

AI Analysis

2025-11-25

downgrade

Neutral -> Underperform

Reason

Wedbush analyst Martin Fan downgraded ImageneBio to Underperform from Neutral with a price target of $2, down from $23, while assuming coverage of the stock. The firm recommends investors avoid ImageneBio shares unless the company either gains a development partner, or shifts its focus to a new indication, citing high development costs, the company's reliance on a single asset and indication, a limited catalyst calendar, and what it views as competitors with equivalent or superior product profiles.

Leerink

Outperform

initiated

$30

2025-10-24

Reason

Leerink

Price Target

$30

2025-10-24

initiated

Outperform

Reason

Leerink initiated coverage of ImageneBio (IMA) with an Outperform rating and $30 price target. The firm views shares as "dramatically undervalued," particularly following a selloff in the wake of disappointing competitor Sanofy's (SNY) amlitelimab results on September 4. Leerink believes ImageneBio's lead asset IMG-007, a non-depleting anti-OX40 monoclonal antibody, is a potential blockbuster for atopic dermatitis. Early clinical data for IMG-007 suggests compelling efficacy at Week 16 compared to Dupixent. Competing drug candidate Phase 3 disappointments from Amgen's (AMGN) OX40 rocatinlimab and Sanofi's OX40L amlitelimab have dampened investor sentiment toward the OX40-OX40L class. This yields a favorable setup for IMG-007 to deliver a superior "trifecta" competitive profile, the firm argues.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMA

Unlock Now

IMA Should I Buy

IMA Should I Buy

Should You Buy ImageneBio Inc (IMA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch